2022 San Antonio Breast Cancer Symposium®

December 6-10, 2022

Available to watch now:

The Evolving Role of the Oncotype DX Breast Recurrence Score® Test and the Future of the Breast Cancer Care Continuum

Learning Objectives

  • Review and provide updates on clinical outcomes in clinical trials involving the Oncotype DX Breast Recurrence Score test.
  • Review the use of genomic assays for radiation decision making.
  • Discuss the clinical impact of germline testing, molecular residual disease (MRD) detection and tumor profiling on the breast cancer care continuum.
Please note that polling responses were only accepted during the live symposium.


Jennifer Racz MD

Director, Medical Affairs, Precision Oncology

Christy Russell MD

Vice President, US Medical Affairs, Precision Oncology

Tuesday, December 06, 2022
Saturday, December 10, 2022

Product Theater


Presentations of Interest

Oral Presentation | Tuesday, 12/6/22 2:00 PM CT
Race and clinical outcomes in the RxPONDER trial (SWOG S1007)
GS10-01 | Abdou

Oral Presentation | Tuesday, 12/6/22 2:45 PM CT
Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
GS1-04 | Kang

Oral Presentation | Tuesday, 12/6/22 3:00 PM CT
Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates
GS1-05 | Sparano

Poster Discussion | Wednesday, 12/7/22 9:45-11:00 AM CT (Final talk in session)
Impact of HER2 low status on clinical outcomes in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): results from SWOG S1007 (RxPONDER)
HER2-19 | Spring